Head & Neck Cancers | Specialty

The head & neck cancers condition center is a comprehensive resource for clinical news and expert insights on head & neck cancers. Read more at OncLive.

PYX-201 Generates Responses and Contributes to Growing ADC Use in Solid Tumors

December 5th 2024

Glenn J. Hanna, MD, discusses data with PYX-201, expanding on the phase 1 trial which evaluated the agent in head and neck squamous cell carcinoma.

Toripalimab Plus Chemo Stands Alone as Preferred Frontline Regimen in Updated NCCN Guidelines for Advanced Nasopharyngeal Carcinoma

December 4th 2024

The NCCN has released updated guidelines for the management of nasopharyngeal carcinoma.

Revisit Every OncLive On Air Episode From November 2024

December 2nd 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

The OncFive: Top Oncology Articles for the Week of 11/17

November 23rd 2024

Zanidatamab scores approval for HER2+ biliary tract cancer, Versamune HPV is under exploration in HPV16+ head and neck squamous cell carcinoma, and more.

Toripalimab Plus Chemo Approved in UK for Frontline Nasopharyngeal Carcinoma and ESCC

November 18th 2024

The UK MHRA approved frontline toripalimab plus chemotherapy for recurrent/metastatic NPC, as well as for advanced, recurrent, or metastatic ESCC.

Versamune HPV Could Bolster Long-Term Efficacy With Pembrolizumab in HPV16-Driven HNSCC

November 18th 2024

Experts discuss the ongoing investigation of Versamune HPV plus pembrolizumab and its potential effect on outcomes in first-line HPV16-driven HNSCC.

Selumetinib Boosts ORR in NF1 With Inoperable Plexiform Neurofibroma

November 12th 2024

Selumetinib led to a statistically significant and clinically meaningful improvement in ORR compared with placebo in adult patients with neurofibromatosis.

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

November 7th 2024

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

The Top News From ESMO 2024: A Variety of Data Inform Solid Tumor Landscapes

November 1st 2024

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

Toripalimab Wins Approval in India and Hong Kong for Recurrent/Metastatic Nasopharyngeal Carcinoma

October 15th 2024

Toripalimab has been approved in India and China’s Hong Kong Special Administrative Region for recurrent or metastatic nasopharyngeal carcinoma.

Dr Tao on the Efficacy of Avelumab/Cetuximab/Radiotherapy in Cisplain-Eligibile vs Ineligible HNSCC

October 14th 2024

Yungan Tao, MD, discusses the efficacy of avelumab plus cetuximab and radiotherapy in patients with head and neck squamous cell carcinoma.

Dr Weiss on Outcomes With Versamune HPV Plus Pembrolizumab in HPV16+ HNSCC

October 14th 2024

Jared Weiss, MD, discusses outcomes with first-line Versamune HPV plus pembrolizumab in HPV16–positive recurrent or metastatic HNSCC.

The OncFive: Top Oncology Articles for the Week of 10/6

October 12th 2024

Inavolisib triplet wins FDA approval in PIK3CA+ breast cancer, perioperative pembrolizumab improves EFS in head and neck cancer, and more from OncLive this week.

2023 Chemotherapy Shortages Drove Altered Treatment Plans, Persistent Cost Increases

October 9th 2024

The 2023 cisplatin shortage led to shifts toward the use of alternative agents for use in head and neck cancer, as well as increased drug costs.

Perioperative Pembrolizumab Meets EFS End Point in Newly Diagnosed, Resected Stage III/IVA HNSCC

October 8th 2024

Perioperative treatment with pembrolizumab and adjuvant radiotherapy improved EFS vs adjuvant radiotherapy in locally advanced head and neck squamous cell carcinoma.

Dr Siu on the Rationale for Combining Petosemtamab With Pembrolizumab in HNSCC

October 4th 2024

Lillian L. Siu, MD, FRCPC, discusses the background for evaluating first-line petosemtamab plus pembrolizumab in recurrent/metastatic PD-L1+ HNSCC.

First-Line Versamune HPV Vaccine Bolsters Responses With SOC Pembrolizumab in HPV16+ Recurrent HNSCC

October 3rd 2024

Jared Weiss, MD, discusses survival benefits seen with the therapeutic cancer vaccine Versamune HPV plus first-line pembrolizumab in HPV16-positive HNSCC.

FDA Approves Selpercatinib for RET Fusion–Positive Medullary Thyroid Cancer

September 27th 2024

The FDA has granted traditional approval to selpercatinib (Retevmo) for advanced or metastatic medullary thyroid cancer with a RET mutation.

Clinical Scenario: Metastatic EBV-Positive NPC

September 25th 2024

The panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.

Toripalimab Plus Chemo Wins European Approval for Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma

September 25th 2024

The European Commission has approved toripalimab in indications for nasopharyngeal carcinoma and esophageal squamous cell carcinoma.